keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonate necrosis

keyword
https://www.readbyqxmd.com/read/28587938/etidronate-down-regulates-toll-like-receptor-tlr-2-ligand-induced-proinflammatory-cytokine-production-by-inhibiting-nf-%C3%AE%C2%BAb-activation
#1
Kentaro Hojo, Riyoko Tamai, Michiyo Kobayashi-Sakamoto, Yusuke Kiyoura
BACKGROUND: Etidronate is a non-nitrogen-containing bisphosphonate (non-NBP) used for anti-bone resorptive therapy as well as having inhibitory effects on atherosclerotic plaques. The present study examined the effects of etidronate on the production of proinflammatory cytokines and chemokines by the macrophage-like cell line, J774.1, incubated with Pam3Cys-Ser-(Lys)4 (Pam3CSK4, a Toll-like receptor (TLR) 2 agonist) and lipid A (a TLR4 agonist). METHODS: J774.1 cells and human monocytic THP-1 cells were pretreated with or without etidronate for 5min, and then incubated with or without Pam3CSK4 or lipid A for 24h...
March 19, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28566618/underlying-mechanisms-and-therapeutic-strategies-for-bisphosphonate-related-osteonecrosis-of-the-jaw-bronj
#2
Yasuo Endo, Hiroyuki Kumamoto, Masanori Nakamura, Shunji Sugawara, Teruko Takano-Yamamoto, Keiichi Sasaki, Tetsu Takahashi
Bisphosphonates (BPs), with a non-hydrolysable P-C-P structure, are cytotoxic analogues of pyrophosphate, bind strongly to bone, are taken into osteoclasts during bone-resorption and exhibit long-acting anti-bone-resorptive effects. Among the BPs, nitrogen-containing BPs (N-BPs) have far stronger anti-bone-resorptive effects than non-N-BPs. In addition to their pyrogenic and digestive-organ-injuring side effects, BP-related osteonecrosis of jaws (BRONJ), mostly caused by N-BPs, has been a serious concern since 2003...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28461645/treatment-response-and-longterm-outcomes-in-children-with-chronic-nonbacterial-osteomyelitis
#3
Anja Schnabel, Ursula Range, Gabriele Hahn, Reinhard Berner, Christian M Hedrich
OBJECTIVE: The autoinflammatory bone disorder chronic nonbacterial osteomyelitis (CNO) covers a wide clinical spectrum, ranging from mild self-limited presentations to chronically active or recurrent courses, which are then referred to as chronic recurrent multifocal osteomyelitis (CRMO). Little is known about treatment options and longterm outcomes. We investigated treatment responses and outcomes in children with CNO. METHODS: A retrospective chart review was conducted in a tertiary referral center, covering 2004-2015...
May 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28401741/oral-alendronate-in-pediatric-chronic-recurrent-multifocal-osteomyelitis
#4
Daishi Hirano, Kosuke Chiba, Saya Yamada, Hiroyuki Ida
Chronic recurrent multifocal osteomyelitis (CRMO) primarily affects children and adolescents, and is characterized by episodic sterile osteomyelitis over several years. No definitive treatment is available. Non-steroidal anti-inflammatory drugs (NSAID) are common first-line agents, but provide limited improvement in bone pain and do not affect disease duration. Several agents are utilized in the case of non-response to NSAID, including corticosteroids, methotrexate, and tumor necrosis factor-blocking agents...
April 2017: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/28401420/an-update-on-the-pathogenesis-and-treatment-of-chronic-recurrent-multifocal-osteomyelitis-in-children
#5
REVIEW
Andrea Taddio, Floriana Zennaro, Serena Pastore, Rolando Cimaz
Chronic recurrent multifocal osteomyelitis (CRMO), also known as chronic non-bacterial osteomyelitis (CNO), is a rare inflammatory disorder that primarily affects children. It is characterized by pain, local bone expansion, and radiological findings suggestive of osteomyelitis, usually at multiple sites. CRMO predominantly affects the metaphyses of long bones, but involvement of the clavicle or mandible are suggestive of the diagnosis. CRMO is a diagnosis of exclusion, and its pathogenesis remains unknown. Differential diagnosis includes infection, malignancies, benign bone tumors, metabolic disorders, and other autoinflammatory disorders...
June 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28365078/macrophage-and-osteoclast-polarization-in-bisphosphonate-associated-necrosis-and-osteoradionecrosis
#6
Falk Wehrhan, Patrick Moebius, Kerstin Amann, Jutta Ries, Raimund Preidl, Friedrich W Neukam, Manuel Weber
PURPOSE: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a complication of antiresorptive therapy with nitrogen-containing bisphosphonates (BP). With various suggestions as to pathogenesis, the etiology of BRONJ is not sufficiently understood. Osteoclasts and their precursors, that is, macrophages, are the main target cells of BP. BP can repolarize regeneration- and healing-associated M2 macrophages towards the tissue destructive M1-type. The current study aims to elucidate differences in macrophage and osteoclast polarization in BRONJ, osteoradionecrosis (ORN) and healthy control specimens...
March 1, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/28314897/transient-osteoporosis-of-the-hip-review-of-the-literature
#7
REVIEW
K Asadipooya, L Graves, L W Greene
Transient osteoporosis of the hip (TOH) is a temporary clinical condition of unknown etiology which usually resolves with conservative therapy though may be complicated by fracture or progression to avascular necrosis (AVN). TOH may be slightly more prevalent in men but when it occurs in women, it is most often seen in the latter part of pregnancy. Though fracture is a rare complication of TOH when it occurs, it is most often associated with TOH occurring in pregnancy. Magnetic resonance imaging (MRI) is the best method to diagnosis TOH...
March 17, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28167963/physicians-perspectives-on-the-diagnosis-and-treatment-of-chronic-nonbacterial-osteomyelitis
#8
Yongdong Zhao, Fatma Dedeoglu, Polly J Ferguson, Sivia K Lapidus, Ronald M Laxer, Miranda C Bradford, Suzanne C Li
Background/Purpose. Understanding the practices of pediatric rheumatologists in diagnosing and treating chronic nonbacterial osteomyelitis (CNO) can provide important information to guide the development of consensus treatment plans. The objectives of this study were to determine physicians' approaches to (1) diagnosing and monitoring CNO, (2) ordering a bone biopsy, and (3) making treatment decisions. Methods. A survey was distributed among members of the Childhood Arthritis and Rheumatology Research Alliance using a web-based questionnaire...
2017: International Journal of Rheumatology
https://www.readbyqxmd.com/read/28101496/medication-related-osteonecrosis-of-the-jaw-a-preliminary-retrospective-study-of-130-patients-with-multiple-myeloma
#9
Woo-Sung Choi, Jae-Il Lee, Hyun-Joong Yoon, Chang-Ki Min, Sang-Hwa Lee
BACKGROUND: Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells primarily in the bone marrow. Bisphosphonates (BP) are used as supportive therapy in the management of MM. This study aimed to analyze the incidence, risk factors, and clinical outcomes of medication-related necrosis of the jaw (MRONJ) in MM patients. METHODS: One hundred thirty MM patients who had previous dental evaluations were retrospectively reviewed. Based on several findings, we applied the staging and treatment strategies on MRONJ...
December 2017: Maxillofacial Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28053907/prevalence-of-osteonecrosis-of-the-jaw-and-oral-characteristics-of-oncologic-patients-treated-with-bisphosphonates-at-the-general-hospital-of-mexico
#10
María Verónica Cuevas-González, Celia Minerva Díaz-Aguirre, Enrique Echevarría-Y-Pérez, Juan Carlos Cuevas-González
OBJECTIVES: To determine the prevalence and oral characteristics of cancer patients treated with bisphosphonates in the oncology and maxillofacial prosthesis departments of the General Hospital of Mexico between 2011 and 2013. MATERIALS AND METHODS: This cross-sectional study included patients who received prior treatment with bisphosphonates; an intraoral examination was performed by 2 standardized examiners. RESULTS: The prevalence of bisphosphonate-related necrosis in 75 patients was 2...
December 2016: Journal of the Korean Association of Oral and Maxillofacial Surgeons
https://www.readbyqxmd.com/read/27993538/sapho-syndrome-in-childhood-a-case-report
#11
Manuel Vargas Pérez, Belén Sevilla Pérez
The acronym of SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) combines a cluster of cutaneous and musculoskeletal manifestations, such as hyperostosis of bones of the anterior chest wall associated with acne fulminans and hidradenitis suppurativa. There are no validated diagnostic criteria in children. Nonsteroidal anti-inflammatory drugs are not always sufficient, and the use of corticosteroids, disease-modifying agents, tumor necrosis factor-α inhibitors or bisphosphonates may be necessary...
December 16, 2016: Reumatología Clinica
https://www.readbyqxmd.com/read/27920815/early-onset-acute-tubular-necrosis-following-single-infusion-of-zoledronate
#12
Ralph Yachoui
Zoledronate is a highly potent bisphosphonate widely used in the treatment of postmenopausal osteoporosis. We report the first occurrence of toxic acute tubular necrosis (ATN) following treatment with zoledronate in a patient with osteoporosis. A 63-year-old Caucasian female with rheumatoid arthritis on anti-immune agents received a single dose of zoledronic acid (reclast) for worsening osteoporosis. Twelve days later, she developed renal failure with a rise in serum creatinine from a baseline level of 1.1 mg/dL to 5...
May 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/27919595/the-starting-point-for-bisphosphonate-related-osteonecrosis-of-the-jaw-alveolar-bone-or-oral-mucosa-a-randomized-controlled-experimental-study
#13
Mohammad Zandi, Arash Dehghan, Pejman Janbaz, Hamid Malekzadeh, Payam Amini
OBJECTIVE: Although over a decade has passed since first introduction of BRONJ, the exact pathophysiology of this disease is still unclear. The present experimental study aimed to determine whether the oral mucosa or alveolar bone serves as the starting point for BRONJ development. SUBJECTS AND METHODS: Sixty male Wistar rats were randomly assigned into study and control groups (each, n = 30), and received intraperitoneal injection of 0.06 mg/kg zoledronate and saline, respectively, once a week for 12 weeks...
January 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/27741546/bisphosphonate-and-medication-related-osteonecrosis-of-the-jaw-a-review
#14
REVIEW
Thomas Mücke, Christian R Krestan, David A Mitchell, Jan S Kirschke, Arno Wutzl
For patients with malignant disease taking bisphosphonates and denosumab, the incidence of medication-related osteonecrosis of the jaw (MRONJ) is up to 15% in contrast to 0.01% in patients with osteoporosis. Clinical presentation of MRONJ extends from asymptomatic exposure of bone in 94% of patients to severe cases of mandibular fractures in a minority of 4.5%. The strongest risk factors for MRONJ are invasive dental procedures and dental infections. Advances in imaging provide more preoperation information compared with panoramic radiograph...
July 2016: Seminars in Musculoskeletal Radiology
https://www.readbyqxmd.com/read/27734985/prevention-of-bisphosphonate-related-mandibular-fractures
#15
M Pedrazzoli, L Autelitano, F Biglioli
Mandibular fracture is usually the clinical end of bisphosphonate-related osteonecrosis of the jaw. This is a painful complication and patients cannot feed as usual, with a worsening of their quality of life. The goal of treatment in bisphosphonate related osteonecrosis of jaw (BRONJ) patients is to slow progression of bone necrosis. We present a novel technique for treatment of severe mandibular BRONJ in stage 3 patients that present with a high risk to develop fracture, since they have a residual unaffected mandibular bone height less than 6 mm...
August 2016: Acta Otorhinolaryngologica Italica
https://www.readbyqxmd.com/read/27648313/denosumab-related-osteonecrosis-of-the-jaw-with-spontaneous-necrosis-of-the-soft-palate-report-of-a-life-threatening-case
#16
Mohammed Qaisi, Jamie Hargett, Matthew Loeb, Jeffrey Brown, Ronald Caloss
Bisphosphonates have been used for years in the treatment of patients with distant bony metastasis and in the prevention of osteoporosis. One of main side effects of these medications is the development of bisphosphonate related osteonecrosis of the jaw (BRONJ) in a small subset of patients. A new class of medications with a shorter half-life, known as receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, was introduced with the hopes of avoiding this side effect. However, reports of osteonecrosis of the jaw after the use of RANKL inhibitors have also been documented...
2016: Case Reports in Dentistry
https://www.readbyqxmd.com/read/27637460/preexisting-periapical-inflammatory-condition-exacerbates-tooth-extraction-induced-bisphosphonate-related-osteonecrosis-of%C3%A2-the%C3%A2-jaw%C3%A2-lesions-in-mice
#17
Minju Song, Abdullah Alshaikh, Terresa Kim, Sol Kim, Michelle Dang, Shebli Mehrazarin, Ki-Hyuk Shin, Mo Kang, No-Hee Park, Reuben H Kim
INTRODUCTION: Surgical interventions such as tooth extraction increase the chances of developing osteonecrosis of the jaw in patients receiving bisphosphonates (BPs) for the treatment of bone-related diseases. Tooth extraction is often performed to eliminate preexisting pathological inflammatory conditions that make the tooth unsalvageable; however, the role of such conditions on bisphosphonate-related osteonecrosis of the jaw (BRONJ) development after tooth extraction is not clearly defined...
November 2016: Journal of Endodontics
https://www.readbyqxmd.com/read/27636578/bisphosphonates-inhibit-pain-bone-loss-and-inflammation-in-a-rat-tibia-fracture-model-of-complex-regional-pain-syndrome
#18
Liping Wang, Tian-Zhi Guo, Tzuping Wei, Wen-Wu Li, Xiaoyou Shi, J David Clark, Wade S Kingery
BACKGROUND: Bisphosphonates are used to prevent the bone loss and fractures associated with osteoporosis, bone metastases, multiple myeloma, and osteogenesis deformans. Distal limb fractures cause regional bone loss with cutaneous inflammation and pain in the injured limb that can develop into complex regional pain syndrome (CRPS). Clinical trials have reported that antiresorptive bisphosphonates can prevent fracture-induced bone loss, inhibit serum inflammatory cytokine levels, and alleviate CRPS pain...
October 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27622181/pamidronate-down-regulates-tumor-necrosis-factor-alpha-induced-matrix-metalloproteinases-expression-in-human-intervertebral-disc-cells
#19
Young-Mi Kang, Seong-Hwan Hong, Jae-Ho Yang, Jin-Cheol Oh, Jin-Oh Park, Byung Ho Lee, Sang-Yoon Lee, Hak-Sun Kim, Hwan-Mo Lee, Seong-Hwan Moon
BACKGROUND: N-containing bisphosphonates (BPs), such as pamidronate and risedronate, can inhibit osteoclastic function and reduce osteoclast number by inducing apoptotic cell death in osteoclasts. The aim of this study is to demonstrate the effect of pamidronate, second generation nitrogen-containing BPs and to elucidate matrix metallo-proteinases (MMPs) mRNA expression under serum starvation and/or tumor necrosis factor alpha (TNF-α) stimulation on metabolism of intervertebral disc (IVD) cells in vitro...
August 2016: Journal of Bone Metabolism
https://www.readbyqxmd.com/read/27555374/prevention-of-bisphosphonate-related-osteonecrosis-of-the-jaws-in-patients-with-prostate-cancer-treated-with-zoledronic-acid-a-prospective-study-over-6-years
#20
Thomas Mücke, Herbert Deppe, Jana Hein, Klaus-Dietrich Wolff, David A Mitchell, Marco R Kesting, Margitta Retz, Jürgen E Gschwend, Mark Thalgott
INTRODUCTION: To explore the preventive effect of a prophylactic oral and maxillofacial treatment to reduce bisphosphonate associated necrosis of the jaws (BRONJ) in metastatic prostate cancer (PC) patients treated with zoledronic acid (4.0 mg i.v./months). MATERIALS AND METHOD: 253 PC patients with bone metastases were prospectively randomized. All patients received baseline assessments including a dental panoramic tomogram. Group A was monitored and treated where deemed necessary by the patient's dentist and were re-evaluated once a year...
October 2016: Journal of Cranio-maxillo-facial Surgery
keyword
keyword
49881
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"